Agamree
Authorised
This medicine is authorised for use in the European Union
vamorolone
MedicineHumanAuthorised
Romanian is available via eTranslation, the European Commission's machine translation service.
Translate to Romanian | Important information about machine translation
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Agamree is a medicine for treating Duchenne muscular dystrophy in patients from 2years of age. Duchenne muscular dystrophy is a genetic disease that gradually causes weakness and loss of muscle function.
Duchenne muscular dystrophy is rare, and Agamree was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 22 August 2014. Further information on the orphan designation can be found on the EMA website.
Agamree contains the active substance vamorolone.
The medicine can only be obtained with a prescription. Treatment should only be started by a specialist doctor with experience in managing Duchenne muscular dystrophy.
Agamree is available as a suspension to be taken by mouth once a day. The doctor will prescribe the dose based on the patient’s bodyweight.
For more information about using Agamree, see the package leaflet or contact your doctor or pharmacist.
The active substance in Agamree, vamorolone, is a modified corticosteroid medicine which reduces inflammation by blocking the production of certain inflammatory substances called cytokines. The way it works in patients with Duchenne muscular dystrophy is not fully understood.
A main study showed that Agamree was more effective than placebo (a dummy treatment) in treating Duchenne muscular dystrophy in patients between the ages of 4 and below 7 years who were able to walk. The study, involving 121 patients, looked at their TTSTAND velocity (time to stand), which is the speed at which they can stand up from a lying position.
After 24 weeks of treatment, the average TTSTAND velocity increased from 0.19 to 0.24 rises per second in patients who took Agamree, while it decreased slightly from 0.20 to 0.19 rises per second in those who had placebo. This effect was maintained up to week 48.
In addition, a study in 20 boys aged 2 to under 4 years, who had not previously received corticosteroids, showed that Agamree works in a similar way to how it works in slightly older children (aged between 4–6 years). The study also showed that Agamree improved the children’s movement skills, with greater improvements seen at higher doses. However, the study did not compare Agamree with another treatment or placebo.
Studies carried out with Agamree are described in more detail in the medicine’s assessment reports.
For the full list of side effects and restrictions with Agamree, see the package leaflet.
The most common side effects with Agamree (which may affect more than 1 in 10 people) include Cushingoid features (features caused by long-term use of a corticosteroid, such as fat build-up on the face and bruising), vomiting, increased weight and irritability.
The medicine must not be used in patients who have severely impaired liver function or who have received a live vaccine (a vaccine that uses a weakened form of the organism) in the 6 weeks before starting treatment or while receiving treatment.
The European Medicines Agency decided that Agamree’s benefits are greater than its risks and it can be authorised for use in the EU.
The data available supports the use of Agamree in patients between 2 and below 7 years of age to improve their ability to move. Given that vamorolone works in the same way as currently used corticosteroids, the Agency concluded that it can be used in older patients as well.
In terms of safety, Agamree compares well with conventional corticosteroids and does not cause some of the side effects that conventional corticosteroids cause (such as effects on the bone and growth).
The company that markets Agamree will provide patients with an alert card with information about the need for daily treatment and the risk of adrenal crisis, a side effect which can occur in patients abruptly stopping corticosteroid treatment.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Agamree have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Agamree are continuously monitored. Suspected side effects reported with Agamree are carefully evaluated and any necessary action is taken to protect patients.
Agamree received a marketing authorisation valid throughout the EU on 14 December 2023.
Product information
Latest procedure affecting product information:VR/0000293535
29/05/2026
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Agamree
- Active substance
- vamorolone
- International non-proprietary name (INN) or common name
- vamorolone
- Therapeutic area (MeSH)
- Muscular Dystrophy, Duchenne
- Anatomical therapeutic chemical (ATC) code
- H02AB18
Pharmacotherapeutic group
GlucocorticoidsTherapeutic indication
Agamree is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.
Assessment history
News on Agamree
This page was last updated on